Acute Leukemia
Acute leukemia is a fast-growing blood cancer marked by the buildup of immature white blood cells in the bone marrow and blood, disrupting normal blood cell production and leading to rapid symptom onset.
Biomarkers used in this indication
Each approval combines this indication with specific biomarker criteria and a therapy. Select a therapy from the tables below to open its FDA-defined testing pathway.
Defined explicitly for Acute Leukemia in FDA labeling.
| Biomarker | Biomarker criteria | Therapies |
|---|---|---|
| KMT2A |
|
Defined at the solid tumor level and applicable to Acute Leukemia and other solid tumor cancers.
No tumor-agnostic biomarker approvals are currently mapped for this indication.
Therapies with biomarker-defined approvals
Each therapy below has at least one FDA companion diagnostic approval tied to Acute Leukemia. Select a therapy to view the specific approval and eligible tests.
KMT2A (Rearrangements on chromosome 11 at location 11q23.3)